[A study of the alveolar-arterial oxygen gradients and intrapulmonary shunt under the action of NAB-365, a new exogenous catecholamine of selective beta-2 action (author's transl)].
Thirty patients were studied using NAB-365 (clenbuterol), an exogenous catecholamine with selective beta-2 action to determine various parameters of pulmonary physiopathology. They included: alveolar-arterial gradients in partial oxygen pressures, coefficient of respiratory inefficacy, alveolar ventilation, and intrapulmonary venoarterial short circuits. By studying these parameters before and after clinical administration of clenbuterol we were able to demonstrate a decrease in the alveolar-arterial oxygen gradients (p less than 0.001), decrease in the respiratory inefficacy coefficient (p less than 0.001), increase in alveolar ventilation (p less than 0.001), and a shunt decrease (p less than 0.0025). The drug improves diffusion and oxygenation without affecting the adrenergic cardiac receptors.
D002976:Clenbuterol / Q000494:pharmacology*; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D004983:Ethanolamines / Q000494:pharmacology*; D005260:Female; D006801:Humans; D008168:Lung / Q000503:physiopathology; D008173:Lung Diseases, Obstructive / Q000175:diagnosis*; D008297:Male; D008875:Middle Aged; D010100:Oxygen / Q000097:blood; D010313:Partial Pressure; D011653:Pulmonary Diffusing Capacity; D011941:Receptors, Adrenergic / Q000187:drug effects; D012129:Respiratory Function Tests; D012131:Respiratory Insufficiency / Q000503:physiopathology
D004983:Ethanolamines; D011941:Receptors, Adrenergic; D010100:Oxygen; D002976:Clenbuterol
Estudio de los gradientes alvéolo-arteriales de oxígeno y shunt intrapulmonar bajo la acción de NAB-365, nueva catecolamina exógena de acción beta-2 selectiva (clenbuterol).